ICU Medical (NASDAQ:ICUI) Stock Gets Price Target Bump from Piper Sandler

ICU Medical (NASDAQ:ICUI) had its target price lifted by research analysts at Piper Sandler from $195.00 to $200.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical instruments supplier’s stock. Piper Sandler‘s price target points to a potential upside of 16.20% from the stock’s current price.

Several other research firms have also issued reports on ICUI. Needham & Company LLC raised their price target on shares of ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a report on Friday, August 7th. BTIG Research boosted their price target on shares of ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Wall Street Zen upgraded shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $200.00 price objective on shares of ICU Medical in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $195.20.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $172.11 on Friday. ICU Medical has a fifty-two week low of $113.37 and a fifty-two week high of $192.85. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The firm has a market capitalization of $4.30 billion, a P/E ratio of 72.01, a P/E/G ratio of 2.17 and a beta of 0.88. The company’s 50 day moving average price is $162.91 and its two-hundred day moving average price is $149.27.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.30. ICU Medical had a return on equity of 8.46% and a net margin of 2.76%. The company had revenue of $556.22 million for the quarter, compared to analysts’ expectations of $552.03 million. During the same period in the previous year, the business posted $2.03 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, equities analysts forecast that ICU Medical will post 7.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ICU Medical news, insider Ben Sousa sold 2,250 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total value of $401,220.00. Following the transaction, the insider directly owned 3,076 shares of the company’s stock, valued at approximately $548,512.32. This trade represents a 42.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Virginia Sanzone sold 4,856 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the completion of the transaction, the vice president directly owned 14,604 shares in the company, valued at approximately $2,463,548.76. The trade was a 24.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 21,830 shares of company stock worth $3,905,003 in the last quarter. Insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Several large investors have recently made changes to their positions in the business. Versant Capital Management Inc increased its stake in shares of ICU Medical by 26.2% during the third quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 65 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of ICU Medical by 1.3% in the third quarter. Nisa Investment Advisors LLC now owns 6,088 shares of the medical instruments supplier’s stock valued at $977,000 after acquiring an additional 79 shares in the last quarter. California Public Employees Retirement System lifted its stake in ICU Medical by 0.3% in the first quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier’s stock worth $3,934,000 after acquiring an additional 90 shares during the period. Allworth Financial LP lifted its stake in ICU Medical by 155.1% in the second quarter. Allworth Financial LP now owns 176 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 107 shares during the period. Finally, Arizona State Retirement System lifted its stake in ICU Medical by 1.7% in the second quarter. Arizona State Retirement System now owns 6,551 shares of the medical instruments supplier’s stock worth $960,000 after acquiring an additional 109 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

Key ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q3 results exceeded expectations: ICU Medical reported earnings of $2.44 per share versus the $2.14 consensus estimate, while revenue of $556.22 million also topped forecasts. Revenue rose 4.4% year over year, and earnings increased from $2.03 per share a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Full-year outlook remains solid: The company reaffirmed its 2026 guidance and expects results at the high end of its forecast range, supporting confidence in its near-term performance. Q3 results and guidance
• Positive Sentiment: Analyst targets moved higher: Piper Sandler raised its target to $200 and maintained an Overweight rating; KeyCorp lifted its target to $189 and also kept an Overweight rating. BTIG reiterated its Buy rating and $200 target. These endorsements signal continued analyst confidence in potential upside. BTIG rating update
• Neutral Sentiment: Management will present at the Jefferies Global Healthcare Conference in London on November 15–18. The appearance may provide an opportunity to discuss the business, but no new financial information was announced. Conference announcement

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.